Hypoxia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP266 MIFTS: 57	Hypoxia Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia ⁵³ ¹⁷ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

EFO ¹⁷ EFO_0009444

UMLS ⁷¹ C0242184

Sources

Summaries for Hypoxia

Novus Biologicals : ⁵⁵ Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to chronic mountain sickness and acute mountain sickness, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Pathways in cancer. The drugs Bosentan and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include endothelial, smooth muscle and prostate, and related phenotypes are Decreased viability and Decreased viability

NINDS : ⁵³ Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death. In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Wikipedia : ⁷⁴ Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply... more...

Sources

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1459)

#	Related Disease	Score	Top Affiliating Genes
1	chronic mountain sickness	31.9	VEGFA EPAS1 EGLN3
2	acute mountain sickness	31.4	VHL VEGFA HIF1AN HIF1A EGLN1
3	renal cell carcinoma, nonpapillary	31.4	VHL VEGFA MTOR HIF1AN HIF1A EPAS1
4	polycythemia	31.1	VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
5	pheochromocytoma	30.8	VHL VEGFA HIF1A EPAS1 EGLN3 EGLN2
6	kidney cancer	30.8	VHL VEGFA MTOR HIF1A EPAS1 CA9
7	soft tissue sarcoma	30.7	VEGFA HIF1A
8	paraganglioma	30.6	VHL HIF1A EPAS1 EGLN1
9	von hippel-lindau syndrome	30.6	VHL VEGFA HIF1A EPAS1 EGLN1
10	hemangioma	30.5	VHL VEGFA MTOR HIF1A
11	ductal carcinoma in situ	30.5	VEGFA HIF1A CA9
12	clear cell renal cell carcinoma	30.5	VHL VEGFA MTOR HIF1A EPAS1 EP300
13	hemangioblastoma	30.4	VHL VEGFA HIF1A EPAS1
14	ovarian clear cell carcinoma	30.4	VEGFA MTOR HIF1A
15	estrogen-receptor positive breast cancer	30.3	VEGFA MTOR HIF1A
16	ovarian clear cell adenocarcinoma	30.1	VEGFA MTOR HIF1A
17	fumarate hydratase deficiency	30.0	VHL HIF1A
18	pheochromocytoma-paraganglioma	30.0	VHL EGLN2 EGLN1
19	renal cell carcinoma, papillary, 1	30.0	VHL VEGFA MTOR HIF1A CA9
20	primary polycythemia	29.9	VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
21	gastrointestinal stromal tumor	29.9	VEGFA HIF1A EPAS1 EP300
22	erythrocytosis, familial, 2	29.9	VHL HIF1AN HIF1A EPAS1 EGLN3 EGLN2
23	acquired polycythemia	29.8	EPAS1 EGLN1
24	clear cell papillary renal cell carcinoma	29.8	VHL CA9
25	retinal hemangioblastoma	29.7	VHL VEGFA HIF1A EPAS1
26	neuroendocrine tumor	29.7	VEGFA MTOR EPAS1
27	hematologic cancer	29.0	VEGFA MTOR KMT2A EP300
28	cerebral hypoxia	11.6
29	anoxia	11.4
30	neonatal hypoxic and ischemic brain injury	11.3
31	pulmonary hypertension owing to lung disease and/or hypoxia	11.2
32	asphyxia neonatorum	11.1
33	exudative vitreoretinopathy 1	11.1
34	polycythemia due to hypoxia	11.1
35	pulmonary hypertension	11.0
36	pulmonary edema	11.0
37	sleep apnea	11.0
38	methemoglobinemia due to deficiency of methemoglobin reductase	11.0
39	respiratory underresponsiveness to hypoxia and hypercapnia	10.9
40	ischemia	10.9
41	apnea of prematurity	10.9
42	severe acute respiratory syndrome	10.9
43	hantavirus pulmonary syndrome	10.9
44	congenital extrahepatic portosystemic shunt	10.9
45	tempi syndrome	10.9
46	pneumothorax, primary spontaneous	10.8
47	methemoglobinemia and ambiguous genitalia	10.8
48	exudative vitreoretinopathy 2, x-linked	10.8
49	exudative vitreoretinopathy 4	10.8
50	tricuspid atresia	10.8

Graphical network of the top 20 diseases related to Hypoxia:

Sources

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:

seizures, fever, dyspnea, vertigo, hemoptysis, cachexia, apnea, headache, syncope, cyanosis, edema, chills, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, cheyne-stokes respiration, coughing, hoarseness, increased sweating, anoxemia, signs and symptoms, respiratory, sneezing, hyperoxia, motor symptom, skin symptoms, physical symptom, physical appearance, body

GenomeRNAi Phenotypes related to Hypoxia according to GeneCards Suite gene sharing:

²⁶ (show all 13)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.8	MTOR
2	Decreased viability	GR00055-A-2	9.8	MTOR
3	Decreased viability	GR00221-A-1	9.8	MTOR VHL
4	Decreased viability	GR00221-A-2	9.8	EGLN3 EP300 VHL
5	Decreased viability	GR00221-A-4	9.8	MTOR
6	Decreased viability	GR00240-S-1	9.8	PSMA7
7	Decreased viability	GR00249-S	9.8	ARNT CITED2 EGLN3 PSMA7 VEGFA VHL
8	Decreased viability	GR00301-A	9.8	EGLN3 VHL
9	Decreased viability	GR00342-S-1	9.8	MTOR
10	Decreased viability	GR00342-S-2	9.8	MTOR
11	Decreased viability	GR00381-A-1	9.8	EGLN2 EGLN3 HIF1AN PSMA7
12	Decreased viability	GR00386-A-1	9.8	ARNT TIGAR
13	Decreased viability	GR00402-S-2	9.8	EGLN1 EGLN3 HIF3A KMT2A PSMA7

MGI Mouse Phenotypes related to Hypoxia:

⁴⁶ (show all 20)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.47	ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2	homeostasis/metabolism	MP:0005376	10.41	ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3	cellular	MP:0005384	10.4	ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4	hematopoietic system	MP:0005397	10.4	ARNT CA9 CITED2 EGLN1 EGLN2 EGLN3
5	immune system	MP:0005387	10.37	ARNT CA9 CITED2 EGLN1 EGLN2 EGLN3
6	growth/size/body region	MP:0005378	10.35	ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7	embryo	MP:0005380	10.34	ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
8	mortality/aging	MP:0010768	10.28	ARNT CA9 CITED2 EGLN1 EGLN3 EP300
9	craniofacial	MP:0005382	10.27	ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
10	endocrine/exocrine gland	MP:0005379	10.2	ARNT CA9 CITED2 EGLN3 EP300 HIF1A
11	muscle	MP:0005369	10.18	EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
12	integument	MP:0010771	10.13	ARNT EGLN1 EGLN2 EGLN3 HIF1A HIF1AN
13	liver/biliary system	MP:0005370	10.13	ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
14	digestive/alimentary	MP:0005381	10.11	CA9 CITED2 EP300 HIF1A TIGAR VEGFA
15	limbs/digits/tail	MP:0005371	10	CITED2 EGLN2 EGLN3 HIF1A KMT2A VEGFA
16	nervous system	MP:0003631	10	ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
17	neoplasm	MP:0002006	9.87	ARNT EP300 HIF1A KMT2A TIGAR VEGFA
18	normal	MP:0002873	9.85	ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
19	renal/urinary system	MP:0005367	9.65	ARNT CITED2 EGLN1 EP300 HIF1A KMT2A
20	respiratory system	MP:0005388	9.28	CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN

Sources

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 414)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bosentan

Approved, Investigational

Phase 4

147536-97-8

104865

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Terbutaline

Approved

Phase 4

23031-25-6

5403

Ipratropium

Approved, Experimental

Phase 4

22254-24-6, 60205-81-4

43232 657309

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

62924

Atropine

Approved, Vet_approved

Phase 4

5908-99-6, 51-55-8

174174

Succinylcholine

Approved

Phase 4

306-40-1

5314

Nebivolol

Approved, Investigational

Phase 4

152520-56-4, 118457-14-0, 99200-09-6

71301

Carvedilol

Approved, Investigational

Phase 4

72956-09-3

2585

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Methazolamide

Approved

Phase 4

554-57-4

4100 5353756

Cetirizine

Approved

Phase 4

83881-51-0

2678

Histamine

Approved, Investigational

Phase 4

51-45-6, 75614-87-8

774

Alprostadil

Approved, Investigational

Phase 4

745-65-3

149351 5280723

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Losartan

Approved

Phase 4

114798-26-4

3961

Doxapram

Approved, Vet_approved

Phase 4

309-29-5

3156

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1

3821

Alfentanil

Approved, Illicit

Phase 4

71195-58-9

51263

Dexmedetomidine

Approved, Vet_approved

Phase 4

113775-47-6

68602 5311068

Trazodone

Approved, Investigational

Phase 4

19794-93-5

5533

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Acetazolamide

Approved, Vet_approved

Phase 4

59-66-5

1986

Amlodipine

Approved

Phase 4

88150-42-9

2162

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 4474-91-3, 11128-99-7

172198

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Creatine

Approved, Investigational, Nutraceutical

Phase 4

57-00-1

586

Cysteine

Approved, Nutraceutical

Phase 4

52-90-4

5862

Maleic acid

Experimental

Phase 4

110-16-7

444266

Endothelin Receptor Antagonists

Phase 4

Insulin, Globin Zinc

Phase 4

insulin

Phase 4

Albuterol

Phase 4

Mydriatics

Phase 4

Ether

Phase 4

Liver Extracts

Phase 4

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 4

Salmeterol xinafoate

Phase 4

94749-08-3

56801

Cholinergic Antagonists

Phase 4

Beclomethasone

Phase 4

4419-39-0

20469

Tiotropium Bromide

Phase 4

136310-93-5

Parasympatholytics

Phase 4

Muscarinic Antagonists

Phase 4

Cholinergic Agents

Phase 4

Central Nervous System Stimulants

Phase 4

Anti-Arrhythmia Agents

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Adrenergic alpha-1 Receptor Antagonists

Phase 4

Interventional clinical trials:

(show top 50) (show all 969)

#	Name	Status	NCT ID	Phase	Drugs
1	Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery	Unknown status	NCT02133638	Phase 4	Sevoflurane;Propofol
2	Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia	Unknown status	NCT01449253	Phase 4	Sildenafil;Bosentan
3	Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF)	Unknown status	NCT00668408	Phase 4
4	Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant	Unknown status	NCT00510770	Phase 4
5	Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation	Unknown status	NCT01595399	Phase 4	atropine;Placebo
6	Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment	Completed	NCT00424970	Phase 4	acetazolamide
7	Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome	Completed	NCT00560586	Phase 4	Budesonide;placebo
8	Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function	Completed	NCT00517725	Phase 4	carvedilol;bisoprolol;Nebivolol
9	Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation	Completed	NCT01692821	Phase 4	100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
10	Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects.	Completed	NCT00924833	Phase 4	placebo;Carvedilol;Nebivolol
11	Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude	Completed	NCT00928655	Phase 4	acetazolamide;placebo
12	Hyperoxia: An Unrecognized Mechanism for Inducing "Hypoxia-Like" Symptoms	Completed	NCT03268590	Phase 4	Oxygen
13	Bispectral Index and Clinical Parameters Evaluation in Different Dental Procedures With Nitrous Oxide and Oxygen Sedation	Completed	NCT02671578	Phase 4	Nitrous Oxide
14	The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue.	Completed	NCT02758470	Phase 4	Acetazolamide;Methazolamide
15	Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers	Completed	NCT01873612	Phase 4
16	Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia	Completed	NCT03192488	Phase 4	Cetirizine;Placebo oral capsule
17	The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia	Completed	NCT02760121	Phase 4	Acetazolamide;Methazolamide;Placebo
18	Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients	Completed	NCT02628106	Phase 4	Lipo-PGE1
19	Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion?	Completed	NCT01722370	Phase 4	Oxygen;Medical air equivalent
20	5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females	Completed	NCT02356107	Phase 4	5-hydroxytryptophan and Creatine monohydrate
21	GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study	Completed	NCT04473274	Phase 4	Pioglitazone
22	Effect of Angiotensin Receptor Blockers on Periodic Breathing During Sleep in Hypoxia	Completed	NCT03335904	Phase 4	Losartan;Placebo
23	Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects.	Completed	NCT01377051	Phase 4	Indacaterol maleate;Placebo
24	Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography	Completed	NCT02171910	Phase 4	Doxapram;Placebo
25	Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study	Completed	NCT01997515	Phase 4	Ketamine;placebo
26	Recruitment Maneuver Increases Oxygenation After Intubation in Hypoxemic ICU Patients: a Randomized Controlled Study	Completed	NCT01014299	Phase 4
27	The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy	Completed	NCT01725464	Phase 4
28	Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial	Completed	NCT01887015	Phase 4
29	The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy：a Prospective Randomized, Double-blind, Placebo-controlled Trial	Completed	NCT01470170	Phase 4	Alfentanil;Normal saline;Propofol
30	Preoxygenation Using Noninvasive Ventilation Prior Intubation in Hypoxemic Patients	Completed	NCT00472160	Phase 4
31	Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes	Completed	NCT04193566	Phase 4	Forxiga
32	Reducing the Need for Intensive Care Unit in Hospitalized Patients With Early Respiratory Failure Using the Non-invasive Ventilation Technique. A Multicentre Randomized Study.	Recruiting	NCT01572337	Phase 4
33	The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS	Recruiting	NCT02321072	Phase 4	Oxygen
34	Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury	Recruiting	NCT02922894	Phase 4	Trazodone;Placebo
35	REgistry-based Randomized Controlled Trial of Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX) A Multicenter, Phase IV, Registry-Based, Randomized Controlled Trial (R-RCT)	Recruiting	NCT03441204	Phase 4	LTOT 24 h/day;LTOT 15h/day
36	A Randomized, Double-blind, Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression Associated With Hypobaric Hypoxia in Females	Recruiting	NCT02922725	Phase 4	5-hydroxytryptophan and Creatine
37	Impact of High-flow Nasal Cannula Oxygen (HFNC) Versus Noninvasive Ventilation Associated With Sleep Quality on Atrial Fibrillation in Hypoxemic Patients After Coronary Surgery	Recruiting	NCT02713737	Phase 4
38	Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes	Recruiting	NCT02589691	Phase 4	Rocuronium
39	Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion	Recruiting	NCT04266665	Phase 4	Dexmedetomidine
40	Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03536455	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
41	Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03539367	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
42	Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03536520	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
43	Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03536507	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
44	Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03537924	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
45	Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03540914	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
46	Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial	Active, not recruiting	NCT03536429	Phase 4	ACETAZOLAMIDE oral capsule;Placebo oral capsule
47	Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls.	Not yet recruiting	NCT04027530	Phase 4	Ertugliflozin 15 mg
48	Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators	Terminated	NCT02058823	Phase 4	Placebo;Placebo;Valsartan;Amlodipine
49	Non-Invasive Ventilation in Early Severe Posttraumatic Hypoxia: a Randomized Controlled Trial	Terminated	NCT00557752	Phase 4
50	Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization	Terminated	NCT01241513	Phase 4	NAC;Placebo

Search NIH Clinical Center for Hypoxia

Sources

Genetic Tests for Hypoxia

Sources

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

⁴⁰

Endothelial, Smooth Muscle, Prostate, Breast, Brain, Bone Marrow, Cortex

Sources

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 30000)

#	Title	Authors	PMID	Year
1	Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. ⁶¹	Taniguchi-Ponciano K...Mercado M	33345622	2021
2	Role of dehydroepiandrosterone sulfate as a scavenging antioxidant: the evidence from Caenorhabditis elegans' nervous system under hypoxia. ⁶¹	Hernandez L...Camargo G	33433471	2021
3	Hypoxia response element-directed expression of bFGF in dental pulp stem cells improve the hypoxic environment by targeting pericytes in SCI rats. ⁶¹	Zhu S...Wang Z	33553827	2021
4	TP53-induced glycolysis and apoptosis regulator alleviates hypoxia/ischemia-induced microglial pyroptosis and ischemic brain damage. ⁶¹	Tan LL...Li M	33269748	2021
5	The individual and combined effects of hypoxia and high-fat diet feeding on nutrient composition and flesh quality in Nile tilapia (Oreochromis niloticus). ⁶¹	Lv HB...Qiao F	33143967	2021
6	Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia. ⁶¹	Duggan TJ...Beharry KD	33377400	2021
7	Involvement of TRPM2 Channel on Hypoxia-Induced Oxidative Injury, Inflammation, and Cell Death in Retinal Pigment Epithelial Cells: Modulator Action of Selenium Nanoparticles. ⁶¹	Ozkaya D...Muhamad S	33389617	2021
8	Tibetan medicine Duoxuekang ameliorates hypobaric hypoxia-induced brain injury in mice by restoration of cerebrovascular function. ⁶¹	Li N...Zhang Y	33246120	2021
9	Functional foods from the tropics to relieve chronic normobaric hypoxia. ⁶¹	Ghattamaneni NKR...Brown L	33333240	2021
10	Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging. ⁶¹	Kesa P...Klener P	33455807	2021
11	Astragaloside IV improves angiogenesis under hypoxic conditions by enhancing hypoxia‑inducible factor‑1α SUMOylation. ⁶¹	Wang B...Hu C	33537820	2021
12	Isolated Plin5-deficient cardiomyocytes store less lipid droplets than normal, but without increased sensitivity to hypoxia. ⁶¹	Li Y...Dalen KT	33373698	2021
13	Metabolic adaptation in hypoxia and cancer. ⁶¹	Paredes F...San Martin A	33444690	2021
14	Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. ⁶¹	Ji W...Ge RL	33422543	2021
15	Trimetazidine alleviates hypoxia/reoxygenation-induced apoptosis in neonatal mice cardiomyocytes via up-regulating HMGB1 expression to promote autophagy. ⁶¹	Lu S...Liu H	32757698	2021
16	Ameliorative Effect of Ananas comosus on Cobalt Chloride-Induced Hypoxia in Caco2 cells via HIF-1α, GLUT 1, VEGF, ANG and FGF. ⁶¹	Basavaraju AM...Raghavan AK	32654099	2021
17	Hypoxia-mediated drug resistance in breast cancers. ⁶¹	McAleese CE...Minchin RF	33278499	2021
18	Double whammy: Nitrate pollution heightens susceptibility to both hypoxia and heat in a freshwater salmonid. ⁶¹	Rodgers EM...De Boeck G	33077222	2021
19	Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment. ⁶¹	Chen Y...Yang J	33024904	2021
20	miR‑212 promotes renal interstitial fibrosis by inhibiting hypoxia‑inducible factor 1‑α inhibitor. ⁶¹	Zhang Y...Li YT	33495813	2021
21	MicroRNA‑153 attenuates hypoxia‑induced excessive proliferation and migration of pulmonary arterial smooth muscle cells by targeting ROCK1 and NFATc3. ⁶¹	Zhao M...Shan L	33495839	2021
22	The pathophysiological mechanism of ischemic stroke after hypobaric hypoxia simulation at high altitude. ⁶¹	Zhu M...Li C	33411214	2021
23	MicroRNA-135b-5p promotes endothelial cell proliferation and angiogenesis in diabetic retinopathy mice by inhibiting Von Hipp-el-Lindau and elevating hypoxia inducible factor α expression. ⁶¹	Liu L...Sui D	33032456	2021
24	Increased ratio of P[v-a]CO2 to C[a-v]O2 without global hypoxia: the case of metformin-induced lactic acidosis. ⁶¹	Andreis DT...Protti A	33202296	2021
25	Hypoxia and Hypoxia-Inducible Factor-1α Regulate Endoplasmic Reticulum Stress in Nucleus Pulposus Cells: Implications of Endoplasmic Reticulum Stress for Extracellular Matrix Secretion. ⁶¹	Novais EJ...Risbud MV	33307037	2021
26	Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors. ⁶¹	Semenza GL	33595388	2021
27	Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. ⁶¹	Codony VL...Tavassoli M	33465746	2021
28	The Expression and Role of Hypoxia-induced Factor-1α in Human Tenon's Capsule Fibroblasts under Hypoxia. ⁶¹	Qin X...Lin M	32767899	2021
29	Brain damage caused by neonatal hypoxia-ischemia and the effects of hypothermia in severe combined immunodeficient (SCID) mice. ⁶¹	Ogawa Y...Tsuji M	33359474	2021
30	Up-regulating lncRNA OIP5-AS1 protects neuron injury against cerebral hypoxia-ischemia induced inflammation and oxidative stress in microglia/macrophage through activating CTRP3 via sponging miR-186-5p. ⁶¹	Chen Y...Li Y	33516048	2021
31	Cutting Edge: Hypoxia-Induced Ubc9 Promoter Hypermethylation Regulates IL-17 Expression in Ulcerative Colitis. ⁶¹	Kumar R...Venuprasad K	33504619	2021
32	Phenotypic plasticity, genetic assimilation, and genetic compensation in hypoxia adaptation of high-altitude vertebrates. ⁶¹	Storz JF...Scott GR	33301891	2021
33	Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction. ⁶¹	Albuquerque LL...Salles C	33414163	2021
34	Response to 'Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction'. ⁶¹	Sanderson JE...Wei YX	33414164	2021
35	Zenglv Fumai Granule protects cardiomyocytes against hypoxia/reoxygenation-induced apoptosis via inhibiting TRIM28 expression. ⁶¹	Zhang XH...Liu SR	33398366	2021
36	Hypoxia-induced inhibition of mTORC1 activity in the developing lung: a possible mechanism for the developmental programming of pulmonary hypertension. ⁶¹	Mundo W...Julian CG	33416457	2021
37	Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension. ⁶¹	Wang L...Huo Y	33300142	2021
38	Physiological resiliency in diving mammals: Insights on hypoxia protection using the Krogh principle to understand COVID-19 symptoms. ⁶¹	Williams TM...Davis RW	33227435	2021
39	The influence of summer hypoxia on sedimentary phosphorus biogeochemistry in a coastal scallop farming area, North Yellow Sea. ⁶¹	Yang B...Xing Q	33250257	2021
40	Exposure to Nitrate Increases Susceptibility to Hypoxia in Fish. ⁶¹	Gomez Isaza DF...Franklin CE	33529124	2021
41	Hypoxia-reoxygenation stress modulates the hepatopancreas transcriptome of Chinese mitten crab Eriocheir sinensis. ⁶¹	Xu Y...Xu Z	33338508	2021
42	The effects of NO on the urea cycle pathway in short-term intermittent hypobaric hypoxia in rats. ⁶¹	Javrushyan H...Trchounian A	33326865	2021
43	Prenatal hypoxia predisposes vascular functional and structural changes associated with oxidative stress damage and depressive behavior in adult offspring male rats. ⁶¹	da Silva TFG...Resende AC	33338483	2021
44	Occlusion of activity dependent synaptic plasticity by late hypoxic long term potentiation after neonatal intermittent hypoxia. ⁶¹	Goussakov I...Drobyshevsky A	33358869	2021
45	Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesis. ⁶¹	Zeng D...Li J	33394687	2021
46	Activation of arginase II by asymmetric dimethylarginine and homocysteine in hypertensive rats induced by hypoxia: a new model of nitric oxide synthesis regulation in hypertensive processes? ⁶¹	Lopez V...Moraga FA	33149269	2021
47	USP7, negatively regulated by miR-409-5p, aggravates hypoxia-induced cardiomyocyte injury. ⁶¹	Xue Q...Guang X	33241864	2021
48	Sustained Hypoxia Reduces GABAergic Modulation on NTS Neurons Sending Projections to Ventral Medulla of Rats. ⁶¹	Pascoaloti-Lima JC...Accorsi-Mendonca D	33421568	2021
49	Association of hypoxia and mitochondrial damage associated molecular patterns in the pathogenesis of vein graft failure: a pilot study. ⁶¹	Thankam FG...Agrawal DK	32861831	2021
50	In vivo evaluation of percutaneous carbon dioxide treatment for improving intratumoral hypoxia using 18F-fluoromisonidazole PET-CT. ⁶¹	Maruyama K...Murakami T	33574946	2021

Sources

Genes for Hypoxia

Genes related to Hypoxia (0 elite genes):

(show all 32)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	KMT2A	Lysine Methyltransferase 2A	Protein Coding	150	Experimental evidence: Regulation ³⁸	28756022
2	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	107.01	GeneCards inferred via : Publications Gene name Summaries Proteins Pathways & Interactions Functions Expressions Drugs & Compounds Domains & Families localization (show sections)
3	EGLN1	Egl-9 Family Hypoxia Inducible Factor 1	Protein Coding	57.14	GeneCards inferred via : Publications Gene name Summaries Proteins Pathways & Interactions Functions (show sections)
4	ARNT	Aryl Hydrocarbon Receptor Nuclear Translocator	Protein Coding	56.76	GeneCards inferred via : Publications Gene name Summaries Proteins Pathways & Interactions Functions (show sections)
5	HIF3A	Hypoxia Inducible Factor 3 Subunit Alpha	Protein Coding	56.41	GeneCards inferred via : Publications Gene name Summaries Proteins Pathways & Interactions Functions (show sections)
6	HYOU1	Hypoxia Up-Regulated 1	Protein Coding	53.67	GeneCards inferred via : Publications Gene name Summaries Proteins Pathways & Interactions Functions (show sections)
7	EPAS1	Endothelial PAS Domain Protein 1	Protein Coding	47.94	GeneCards inferred via : Publications Gene name Proteins Pathways & Interactions Functions (show sections)
8	VHL	Von Hippel-Lindau Tumor Suppressor	Protein Coding	47.49	GeneCards inferred via : Publications Summaries Proteins Pathways & Interactions Functions (show sections)
9	HIF1AN	Hypoxia Inducible Factor 1 Subunit Alpha Inhibitor	Protein Coding	46.65	GeneCards inferred via : Publications Gene name Proteins Pathways & Interactions Functions (show sections)
10	EGLN2	Egl-9 Family Hypoxia Inducible Factor 2	Protein Coding	46.18	GeneCards inferred via : Publications Gene name Summaries Pathways & Interactions Functions (show sections)
11	EGLN3	Egl-9 Family Hypoxia Inducible Factor 3	Protein Coding	46.08	GeneCards inferred via : Publications Gene name Proteins Pathways & Interactions Functions (show sections)
12	CITED2	Cbp/P300 Interacting Transactivator With Glu/Asp Rich Carboxy-Terminal Domain 2	Protein Coding	42.25	GeneCards inferred via : Publications Summaries Proteins Pathways & Interactions Functions (show sections)
13	EP300	E1A Binding Protein P300	Protein Coding	36.28	GeneCards inferred via : Publications Summaries Proteins Pathways & Interactions (show sections)
14	HILPDA	Hypoxia Inducible Lipid Droplet Associated	Protein Coding	35.41	GeneCards inferred via : Publications Gene name Proteins Functions (show sections)
15	P4HTM	Prolyl 4-Hydroxylase, Transmembrane	Protein Coding	35.11	GeneCards inferred via : Publications Gene name Summaries Functions (show sections)
16	TIGAR	TP53 Induced Glycolysis Regulatory Phosphatase	Protein Coding	33.18	GeneCards inferred via : Publications Proteins Functions localization (show sections)
17	PSMA7	Proteasome 20S Subunit Alpha 7	Protein Coding	32.96	GeneCards inferred via : Publications Summaries Pathways & Interactions Functions (show sections)
18	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	28.85	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
19	CA9	Carbonic Anhydrase 9	Protein Coding	27.51	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
20	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	25.77	GeneCards inferred via : Publications Functions localization (show sections)
21	CREBBP	CREB Binding Protein	Protein Coding	25.47	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
22	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	25.17	GeneCards inferred via : Publications Proteins Pathways & Interactions (show sections)
23	PDK1	Pyruvate Dehydrogenase Kinase 1	Protein Coding	25.15	GeneCards inferred via : Publications Proteins Functions (show sections)
24	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	25.05	GeneCards inferred via : Publications Proteins Pathways & Interactions (show sections)
25	HIGD1A	HIG1 Hypoxia Inducible Domain Family Member 1A	Protein Coding	24.95	GeneCards inferred via : Gene name Pathways & Interactions Functions (show sections)
26	SESN2	Sestrin 2	Protein Coding	24.74	GeneCards inferred via : Publications Gene name Functions (show sections)
27	CUL2	Cullin 2	Protein Coding	24.73	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
28	HIGD2A	HIG1 Hypoxia Inducible Domain Family Member 2A	Protein Coding	24.64	GeneCards inferred via : Publications Gene name Summaries (show sections)
29	REST	RE1 Silencing Transcription Factor	Protein Coding	24.58	GeneCards inferred via : Publications Functions localization (show sections)
30	RORA	RAR Related Orphan Receptor A	Protein Coding	24.46	GeneCards inferred via : Publications Proteins Functions (show sections)
31	SIAH2	Siah E3 Ubiquitin Protein Ligase 2	Protein Coding	24.43	GeneCards inferred via : Publications Summaries Functions (show sections)
32	HIPK2	Homeodomain Interacting Protein Kinase 2	Protein Coding	24.43	GeneCards inferred via : Publications Proteins Functions (show sections)

Sources

Variations for Hypoxia

Sources

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Sources

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	CDK-mediated phosphorylation and removal of Cdc6 ⁶⁵ Show member pathways ABC transporter disorders ⁶⁵ ABC transporters ³⁶ ABC transporters in lipid homeostasis ⁶⁵ ABC-family proteins mediated transport ⁶⁵ Activation of APC/C and APC/C-Cdc20 mediated degradation of mitotic proteins ⁶⁵ Activation of NF-kappaB in B cells ⁶⁵ APC/C-Cdc20 mediated degradation of mitotic proteins ⁶⁵ APC/C-Cdc20 mediated degradation of Securin ⁶⁵ APC/C-Cdh1 mediated degradation of Cdc20 and other APC/C-Cdh1 targeted proteins in late mitosis/early G1 ⁶⁵ APC/C-mediated degradation of cell cycle proteins ⁶⁵ APC-Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint ⁶⁵ Apoptosis ⁶⁵ Assembly of the pre-replicative complex ⁶⁵ Association of licensing factors with the pre-replicative complex ⁶⁵ Asymmetric localization of PCP proteins ⁶⁵ AUF1 (hnRNP D0) binds and destabilizes mRNA ⁶⁵ Autodegradation of Cdh1 by Cdh1-APC/C ⁶⁵ Autodegradation of the E3 ubiquitin ligase COP1 ⁶⁵ Beta-catenin independent WNT signaling ⁶⁵ Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA ⁶⁵ Ca2+ pathway ⁶⁵ Canonical Wnt Pathway ⁶⁶ Cdc20-Phospho-APC/C mediated degradation of Cyclin A ⁶⁵ CDC6 association with the ORC-origin complex ⁶⁵ CDT1 association with the CDC6-ORC-origin complex ⁶⁵ Cellular response to hypoxia ⁶⁵ Conversion from APC/C-Cdc20 to APC/C-Cdh1 in late anaphase ⁶⁵ creatine biosynthesis ¹ Creatine metabolism ⁶⁵ creatine-phosphate biosynthesis ¹ Cross-presentation of soluble exogenous antigens (endosomes) ⁶⁵ Cyclin A-Cdk2-associated events at S phase entry ⁶⁵ Cyclin E associated events during G1/S transition ⁶⁵ Dectin-1 mediated noncanonical NF-kB signaling ⁶⁵ Defective CFTR causes cystic fibrosis ⁶⁵ Defective TRP may confer susceptibility towards thyroid papillary carcinoma (TPC) ⁶⁵ Degradation of AXIN ⁶⁵ Degradation of beta-catenin by the destruction complex ⁶⁵ Degradation of DVL ⁶⁵ Degradation of GLI1 by the proteasome ⁶⁵ Degradation of GLI2 by the proteasome ⁶⁵ Disorders of transmembrane transporters ⁶⁵ DNA Replication ⁶⁵ DNA Replication Pre-Initiation ⁶⁵ Establishment of Sister Chromatid Cohesion ⁶⁵ FBXL7 down-regulates AURKA during mitotic entry and in early mitosis ⁶⁵ FCERI mediated NF-kB activation ⁶⁵ G1/S DNA Damage Checkpoints ⁶⁵ GLI3 is processed to GLI3R by the proteasome ⁶⁵ Hedgehog ligand biogenesis ⁶⁵ Hh mutants abrogate ligand secretion ⁶⁵ Hh mutants that dont undergo autocatalytic processing are degraded by ERAD ⁶⁵ HHAT G278V abrogates palmitoylation of Hh-Np ⁶⁵ HuR (ELAVL1) binds and stabilizes mRNA ⁶⁵ Interconversion of polyamines ⁶⁵ KSRP (KHSRP) binds and destabilizes mRNA ⁶⁵ M/G1 Transition ⁶⁵ MAPK6/MAPK4 signaling ⁶⁵ Metabolism of polyamines ⁶⁵ Mitochondrial ABC transporters ⁶⁵ NIK-->noncanonical NF-kB signaling ⁶⁵ Orc1 removal from chromatin ⁶⁵ Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha ⁶⁵ p53-Dependent G1 DNA Damage Response ⁶⁵ p53-Dependent G1/S DNA damage checkpoint ⁶⁵ p53-Independent DNA Damage Response ⁶⁵ p53-Independent G1/S DNA damage checkpoint ⁶⁵ PAOs oxidise polyamines to amines ⁶⁵ PCP/CE pathway ⁶⁵ Phosphorylation of the APC/C ⁶⁵ Programmed Cell Death ⁶⁵ Proteasome ³⁶ Proteasome Degradation ¹ PTK6 Regulates Cell Cycle ⁶⁵ Regulation of activated PAK-2p34 by proteasome mediated degradation ⁶⁵ Regulation of APC/C activators between G1/S and early anaphase ⁶⁵ Regulation of Apoptosis ⁶⁵ Regulation of DNA replication ⁶⁵ Regulation of gene expression by Hypoxia-inducible Factor ⁶⁵ Regulation of Hypoxia-inducible Factor (HIF) by oxygen ⁶⁵ Regulation of mitotic cell cycle ⁶⁵ Regulation of mRNA stability by proteins that bind AU-rich elements ⁶⁵ Regulation of ornithine decarboxylase (ODC) ⁶⁵ Regulation of PAK-2p34 activity by PS-GAP/RHG10 ⁶⁵ Regulation of RAS by GAPs ⁶⁵ Release of Hh-Np from the secreting cell ⁶⁵ Removal of licensing factors from origins ⁶⁵ Repression of WNT target genes ⁶⁵ S Phase ⁶⁵ SCF(Skp2)-mediated degradation of p27/p21 ⁶⁵ SCF-beta-TrCP mediated degradation of Emi1 ⁶⁵ SLC transporter disorders ⁶⁵ Stabilization of p53 ⁶⁵ Switching of origins to a post-replicative state ⁶⁵ Synthesis of DNA ⁶⁵ TCF7L2 mutants dont bind CTBP ⁶⁵ The role of GTSE1 in G2/M progression after G2 checkpoint ⁶⁵ TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway ⁶⁵ TNFR2 non-canonical NF-kB pathway ⁶⁵ Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA ⁶⁵ Ubiquitin Mediated Degradation of Phosphorylated Cdc25A ⁶⁵ Ubiquitin-dependent degradation of Cyclin D ⁶⁵ Ubiquitin-dependent degradation of Cyclin D1 ⁶⁵ UCH proteinases ⁶⁵ urea cycle ¹ Urea cycle ⁶⁵ Vif-mediated degradation of APOBEC3G ⁶⁵ Vpu mediated degradation of CD4 ⁶⁵ WNT5A-dependent internalization of FZD2, FZD5 and ROR2 ⁶⁵ WNT5A-dependent internalization of FZD4 ⁶⁵	14.23	VHL VEGFA PSMA7 HIF3A HIF1AN HIF1A
2	Pathways in cancer ³⁶	12.88	VHL VEGFA MTOR HIF1A EPAS1 EP300
3	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.66	VHL VEGFA MTOR HIF1A EPAS1 EP300
4	Cellular Senescence (REACTOME) ⁶⁵ Show member pathways Cellular responses to stress ⁶⁵ Cellular Senescence ⁶⁵ Oxidative Stress Induced Senescence ⁶⁵	12.45	VHL VEGFA PSMA7 MTOR HIF3A HIF1AN
5	Translational Control ⁴	12.32	MTOR HIF1AN HIF1A EPAS1 EGLN1 CA9
6	Angiogenesis (CST) ⁴	11.9	HIF1AN HIF1A EP300 EGLN1 CA9 ARNT
7	Signaling events mediated by VEGFR1 and VEGFR2 ¹ Show member pathways VEGFR1 specific signals ¹	11.89	VHL VEGFA HIF1A EPAS1 ARNT
8	HIF-1 signaling pathway ³⁶	11.85	VHL VEGFA MTOR HIF1A EP300 EGLN3
9	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁵ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁵ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁵ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁵ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁵ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁵ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁵	11.75	VEGFA EP300 CITED2
10	HIF-1-alpha transcription factor network ¹	11.74	VEGFA HIF1A EP300 EGLN3 EGLN1 CITED2
11	Transcription Ligand-dependent activation of the ESR1/SP pathway ²³ Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²³	11.69	VEGFA HIF1A EP300 ARNT
12	HIF1Alpha Pathway ⁶³	11.64	VHL VEGFA PSMA7 HIF1AN HIF1A EP300
13	Central carbon metabolism in cancer ³⁶	11.62	TIGAR MTOR HIF1A
14	Photodynamic therapy-induced HIF-1 survival signaling ¹	11.48	VEGFA HIF1AN HIF1A EGLN1 ARNT
15	HIF Repressor Pathways ⁶⁴ Show member pathways HIF Enhancer Pathways ⁶⁴ Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha ⁶⁵	11.47	HIF1AN HIF1A EPAS1 EP300 EGLN3 CITED2
16	Notch-mediated HES/HEY network ¹	11.44	HIF1A EP300 ARNT
17	Aryl Hydrocarbon Receptor ¹	11.43	VEGFA EP300 ARNT
18	HIF-2-alpha transcription factor network ¹	11.19	VHL VEGFA HIF1AN EPAS1 EP300 EGLN3
19	Angiogenesis (WikiPathways) ¹	11.12	VEGFA HIF1A ARNT
20	Hypoxic and oxygen homeostasis regulation of HIF-1-alpha ¹	11.01	VHL HIF3A HIF1AN HIF1A ARNT
21	Amplification and Expansion of Oncogenic Pathways as Metastatic Traits ¹	10.96	VHL VEGFA EPAS1
22	miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma ¹	10.67	VEGFA HIF1AN HIF1A

Sources

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:0005829	10.07	VHL TIGAR PSMA7 MTOR KMT2A HILPDA
2	cytoplasm	GO:0005737	10.03	VHL VEGFA TIGAR PSMA7 MTOR HIF3A
3	nucleus	GO:0005634	9.86	VHL TIGAR PSMA7 MTOR KMT2A HIF3A
4	transcription factor complex	GO:0005667	9.62	HIF1A EPAS1 EP300 ARNT
5	nucleoplasm	GO:0005654	9.47	VHL PSMA7 MTOR KMT2A HILPDA HIF3A

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.1	VEGFA KMT2A HIF1A EPAS1 EP300 CITED2
2	regulation of transcription, DNA-templated	GO:0006355	10.1	VHL KMT2A HIF3A HIF1A EPAS1 EP300
3	positive regulation of transcription, DNA-templated	GO:0045893	10.02	VHL KMT2A HIF1A EP300 CITED2 ARNT
4	negative regulation of apoptotic process	GO:0043066	10	VHL VEGFA HYOU1 HIF1A CITED2
5	positive regulation of gene expression	GO:0010628	9.97	VEGFA MTOR HIF1A EP300 CITED2
6	negative regulation of gene expression	GO:0010629	9.92	VHL VEGFA HIF1A CITED2
7	angiogenesis	GO:0001525	9.88	VEGFA HIF3A HIF1A EPAS1
8	post-translational protein modification	GO:0043687	9.88	VHL PSMA7 HIF3A HIF1A EPAS1
9	cellular response to hypoxia	GO:0071456	9.85	VEGFA TIGAR MTOR HYOU1 HILPDA HIF1A
10	lung development	GO:0030324	9.78	VEGFA EPAS1 EP300
11	positive regulation of endothelial cell proliferation	GO:0001938	9.73	VEGFA MTOR HIF1A ARNT
12	response to hypoxia	GO:0001666	9.7	VEGFA HIF3A HIF1A EPAS1 EP300 EGLN3
13	outflow tract morphogenesis	GO:0003151	9.69	VEGFA HIF1A CITED2
14	embryonic hemopoiesis	GO:0035162	9.62	KMT2A HIF1A
15	embryonic placenta development	GO:0001892	9.62	HIF1A EPAS1 CITED2 ARNT
16	positive regulation of vascular endothelial growth factor receptor signaling pathway	GO:0030949	9.61	HIF1A ARNT
17	surfactant homeostasis	GO:0043129	9.59	VEGFA EPAS1
18	regulation of transcription from RNA polymerase II promoter in response to oxidative stress	GO:0043619	9.58	HIF1A EPAS1 ARNT
19	oxygen homeostasis	GO:0032364	9.57	HIF1A EGLN1
20	peptidyl-proline hydroxylation to 4-hydroxy-L-proline	GO:0018401	9.56	P4HTM EGLN3 EGLN2 EGLN1
21	regulation of protein neddylation	GO:2000434	9.54	HIF1A EPAS1
22	negative regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061428	9.54	VHL HIF1AN CITED2
23	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.52	VEGFA HIF1A
24	positive regulation of hormone biosynthetic process	GO:0046886	9.46	HIF1A ARNT
25	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061418	9.44	VHL VEGFA PSMA7 HIF3A HIF1AN HIF1A

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	10.5	VHL VEGFA TIGAR PSMA7 MTOR KMT2A
2	oxidoreductase activity	GO:0016491	9.93	P4HTM HIF1AN EGLN3 EGLN2 EGLN1
3	transcription factor binding	GO:0008134	9.89	VHL HIF1A EPAS1 EP300 ARNT
4	protein dimerization activity	GO:0046983	9.81	HIF3A HIF1A EPAS1 ARNT
5	iron ion binding	GO:0005506	9.76	P4HTM EGLN3 EGLN2 EGLN1
6	dioxygenase activity	GO:0051213	9.72	P4HTM HIF1AN EGLN3 EGLN2 EGLN1
7	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	GO:0016705	9.71	P4HTM EGLN3 EGLN2 EGLN1
8	histone acetyltransferase binding	GO:0035035	9.61	HIF1A EPAS1 CITED2
9	ferrous iron binding	GO:0008198	9.56	HIF1AN EGLN3 EGLN2 EGLN1
10	peptidyl-proline dioxygenase activity	GO:0031543	9.54	EGLN3 EGLN2 EGLN1
11	oxygen sensor activity	GO:0019826	9.48	HIF1AN EGLN2
12	peptidyl-proline 4-dioxygenase activity	GO:0031545	9.33	EGLN3 EGLN2 EGLN1
13	L-ascorbic acid binding	GO:0031418	9.26	P4HTM EGLN3 EGLN2 EGLN1
14	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors	GO:0016706	9.02	P4HTM HIF1AN EGLN3 EGLN2 EGLN1

Sources

Sources for Hypoxia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia